Junshi Bio (01877.HK) announced that it has received the "Drug Registration Certificate" issued by the National Medical Products Administration, approving the listing application for Teriprizumab (commodity name: Tuoyi, product code: JS001) combined with Etoposide Phosphate and Platinum for the first-line treatment of extensive-stage small-cell lung cancer.
君實生物(01877.HK)特瑞普利單抗新適應症上市申請獲批
Junshi Bio (01877.HK) received approval for the new indication of Trastuzumab injection.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.